Broad Spectrum Antibiotic: Classes and Application

The term broad spectrum antibiotic does not refer to a single drug, but rather to substance classes with a wide spectrum of activity. Unlike narrow spectrum antibiotics, which target specific pathogen groups, broad spectrum antibiotics cover many gram positive and gram negative bacteria and often also anaerobes. They are essential in emergency medicine, for life threatening infections with unknown pathogens, and in patients with serious comorbidities. At the same time, they are the driving force behind resistance development and collateral damage to the microbiome, which is why their use must be carefully weighed.

A central task of modern antibiotic therapy is the balance between effective treatment and preservation of the antibiotic arsenal. Antibiotic Stewardship Programs in hospitals and practices support physicians in selecting the right antibiotic at the right dose for the shortest reasonable duration. Patients contribute by not practising self medication with leftover antibiotics, completing therapy as prescribed, and not insisting on antibiotics for viral infections.

What Broad Spectrum Means

The spectrum of activity of an antibiotic describes which pathogen groups it is clinically effective against. Broad spectrum means that the substance covers both gram positive and gram negative bacteria, often supplemented by anaerobes or atypical pathogens such as mycoplasmas or chlamydiae. Narrow spectrum targets a specific pathogen group, such as penicillin G against streptococci or flucloxacillin against methicillin sensitive staphylococci.

Important classes with broad spectrum profiles are:

• Aminopenicillins with beta lactamase inhibitors such as amoxicillin clavulanic acid or ampicillin sulbactam for outpatient and inpatient infections of moderate severity
• Acylaminopenicillins such as piperacillin tazobactam for severe inpatient infections including pseudomonas
• Third and fourth generation cephalosporins such as ceftriaxone, cefotaxime, cefepim and ceftazidim for pneumonia, meningitis and nosocomial infections
• Carbapenems such as meropenem, imipenem, ertapenem as reserve for very severe infections or ESBL producing pathogens
• Fluoroquinolones such as ciprofloxacin, levofloxacin, moxifloxacin for specific indications, with relevant safety warnings
• Tetracyclines such as doxycycline in outpatient use with good spectrum against atypical pathogens
• Glycylcyclines such as tigecycline as reserve antibiotic against multiresistant pathogens

A combination of several substances can further extend the spectrum, but brings additional risks and side effects. A broad spectrum does not automatically mean better, but often riskier if a targeted antibiotic would suffice.

Areas of Application

• Severe infections with unknown pathogen, such as sepsis, severe pneumonia, intra abdominal infections, febrile neutropenia
• Initial therapy for life threatening infections, with targeted adjustment after pathogen detection
• Pyelonephritis and urosepsis, when local resistance patterns preclude narrower acting antibiotics
• Complicated skin infections with mixed flora or in diabetes
• Endocarditis with unknown pathogen, reduction to targeted antibiotic after antibiogram
• Postoperative infections after abdominal procedures, often with anaerobe coverage

For simple self limiting respiratory infections, viral infections, community acquired urinary tract infections or mild skin conditions, broad spectrum antibiotics are not first choice. Narrow spectrum antibiotics or no antibiotics at all are sufficient here.

Selection and Dosage

Choice of substance: depends on suspected diagnosis, local resistance patterns, comorbidities, previous antibiotics and individual allergies. Guidelines provide empirical recommendations that are refined by pathogen detection and antibiogram.

Dosage: each antibiotic has its own dosage ranges, which are adjusted according to infection severity, body weight, kidney and liver function as well as pathogen susceptibility. Pharmacokinetic and pharmacodynamic knowledge (time or concentration dependent activity) determines the optimal dosing interval.

Duration of therapy: in many indications, significantly shorter therapies are now sufficient (for example, five to seven days for pneumonia, three days for uncomplicated urinary tract infection). Long indiscriminate therapies promote resistance and side effects. Seven days of therapy is not a law of nature, but a rule of thumb with increasing differentiation.

De escalation: after the antibiogram results arrive, therapy is switched to the narrowest effective antibiotic. This strategy is a core component of modern antibiotic therapy.

Side Effects and Consequences

Class wide frequently: diarrhea, nausea, abdominal pain, rash, allergic reactions.

Microbiome effects: broad spectrum antibiotics reduce the natural bacterial flora in the intestine and favour pathogenic microorganisms. Consequences include diarrhea, fungal infections (candida), clostridioides difficile associated diarrhea and potentially altered susceptibility to other diseases over time.

Resistance development: each antibiotic use selects for resistant bacteria. Broad spectrum antibiotics do so to a much greater extent. Multiresistant pathogens such as ESBL producing enterobacteria, MRSA, VRE or carbapenem resistant pathogens are a consequence of indiscriminate use.

Class specific risks: fluoroquinolones can cause tendon ruptures, aortic aneurysms and neuromuscular symptoms, which is why they should only be used after strict indication. Tetracyclines cause photosensitivity and are contraindicated in children under 8 years. Carbapenems can trigger seizures in renal insufficiency.

Allergies: beta lactams have the highest allergy risk, severe allergic reactions are rare but life threatening. Careful medical history is essential.

Drug Interactions

• Hormonal contraceptives: with recurrent diarrhea potentially reduced efficacy, clinical relevance disputed and class dependent.
• Vitamin K antagonists (warfarin, phenprocoumon): many antibiotics alter INR by interfering with vitamin K metabolism or via the gut flora, monitoring in the first treatment week.
• QT prolonging substances: macrolides and fluoroquinolones can prolong QT interval, combination with other QT prolonging drugs critical.
• Calcium channel blockers, statins, immunosuppressants: interactions via CYP3A4 with macrolides, triazoles and some antibiotics possible.
• Vancomycin plus piperacillin tazobactam: increased risk of acute kidney injury.
• High dose methotrexate: interaction with penicillins with risk of increased MTX toxicity.
• Anticoagulants: overall increased bleeding risk with concomitant medication.

Special Information

Antibiotic Stewardship: selection, dosage and duration of therapy are increasingly being systematically reviewed. Structured programs in hospitals have proven to improve patient outcomes and care results.

Probiotics and microbiome: with prolonged antibiotic therapy, probiotic supplementation can reduce diarrhea. Routine recommendation is not given for simple short term therapies. More important are adequate fluid intake, light diet and medical consultation for severe diarrhea.

Avoid self medication: do not store or use leftover antibiotics from previous therapies. Inadequate or incorrect therapy increases resistance and endangers personal care in case of actual illness.

Medication adherence: follow prescribed dose and duration, even if symptoms have already subsided. Premature cessation of therapy promotes resistance development and relapse.

When to see a doctor: for severe bloody diarrhea, fever above 38.5 degrees celsius, persistent complaints despite therapy, severe rash or shortness of breath, seek immediate medical attention. Suspected anaphylaxis is an emergency.

Lifestyle with recurrent infections: with frequent respiratory or urinary tract infections, thorough diagnostics for possible causes such as immune defects, anatomical abnormalities or chronic diseases are worthwhile. Continuous antibiotic prophylaxis should be used very restrictively.

You May Also Be Interested In

• Piperacillin, acylaminopenicillin from the reserve group
• Clavulanic acid, beta lactamase inhibitor in combination preparations
• Meropenem, carbapenem as reserve for very severe infections
• Doxycycline, outpatient tetracycline with good profile for atypical pathogens
• Vancomycin, glycopeptide for MRSA and severe gram positive infections

Frequently Asked Questions

Sources

• Gelbe Liste, Antibiotics and substance classes
• BfArM, Federal Institute for Drugs and Medical Devices
• AWMF, Guidelines for sepsis, pneumonia, urinary tract infection and Antibiotic Stewardship
• Robert Koch Institute, antibacterial resistance surveillance